Pediatric liver diseases

摘要

Progress in recognizing and treating pediatric liver diseases has accelerated remarkably in the past decade. In part, this is attributable to newly available translational technologies, advances in the fields of genomics and immunology, innovations in stem cell biology, and expanding opportunities in organizing and financing multicenter clinical trials. In the United States, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has funded several clinical consortia focusing on pediatric liver diseases, such as the Nonalcoholic Steatohe-patitis Clinical Research Network (NASH CRN), the Cholestatic Liver Disease Research and Education Network (ChiLDREN), the Pediatric Acute Liver Failure Network (PALFSG), and the Drug-Induced Liver Injury Network (DILIN). These networks have provided the patient volume and mix, perspective, talent, and finances needed to address significant problems in pediatric hepatology. The organization made possible by our professional societies further accelerates progress.